If you're on the lookout for some dividend shares to add to your portfolio, then you may want to check out the ones listed below.
Here's why these ASX dividend shares could be in the buy zone:
Image source: Getty Images
Aventus Group (ASX: AVN)
The first ASX dividend share to look at is Aventus. It is a fully integrated owner, manager, and developer of large format retail centres in Australia.
At the last count, Aventus had a portfolio of 20 centres valued at $2.2 billion and spanning 536,000m2 in gross leasable area. It also has a diverse tenant base of 593 quality tenancies, with national retailers representing 87% of the total portfolio.
Demand for the company's tenancies has remained strong during the pandemic, underpinning strong rental collections. This led to a 6.5% increase in funds from operations (FFO) to $55.9 million during the first half. In addition, a recent update reveals that the valuation of its properties has increased 12% since then.
One broker that is very positive on the company is Goldman Sachs. It currently has a buy rating and $3.27 price target on its shares. This compares to the latest Aventus share price of $3.15.
Goldman is also forecasting yields of approximately 5.4%, 6.1%, and 6.6%, respectively, between FY 2021 and FY 2023.
Integral Diagnostics Ltd (ASX: IDX)
Another ASX dividend share to look at is Integral Diagnostics. It is a medical imaging service provider that operates from a total of 72 radiology clinics across the country.
As with Aventus, Integral Diagnostics has been a solid performer in FY 2021. For example, during the first half of FY 2021, it reported a 29.5% increase in revenue to $170.7 million and a 61.1% jump in net profit after tax to $23.2 million.
Goldman Sachs is also positive on Integral Diagnostics and has a buy rating and $5.50 price target on its shares. The broker believes it is a well-run business in an attractive industry, with a relatively secure volume profile of mid/high single digit growth, and a clear path for further growth through brownfield and M&A activities.
Its analysts are forecasting fully franked dividends per share of 11 cents, 14 cents, and 15 cents between FY 2021 and FY 2023. Based on the latest Integral Diagnostics share price of $5.36, this will mean yields of 2%, 2.6%, and 2.8%, respectively.
